Core C: Assessment Core
Core C: Assessment Core
批准号:
10698078
负责人:
STEPHEN M KANNE
金额:
$18.04万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-06 至 2027-08-31
关键词:
AffectAgeAge MonthsAppointmentAttitudeAutism DiagnosisAutism diagnosticBehavioralBiologicalBirthBrainChildChildhoodClinicalCognitiveCollaborationsCommunicationCommunitiesComputer AnalysisDataDecision MakingDevelopmentDevelopmental Delay DisordersDiagnosisDiagnosticDiagnostic ProcedureDoctor of PhilosophyEarly InterventionElementsEnsureEvaluationFundingGenetic RiskGenomicsHospitalsInfantInformation CentersInterventionKnowledgeLanguageLeadLinkMatched GroupMolecular GeneticsMonitorNeonatal ScreeningNeurodevelopmental DisorderNew YorkNewborn InfantOutcome MeasureParentsParticipantPersonal SatisfactionPhenotypePopulations at RiskPresbyterian ChurchProceduresProviderPsychiatristPsychologistResearchResearch Project GrantsResourcesRiskScreening procedureSourceStandardizationStatistical Data InterpretationStressSurveysSymptomsTrainingUniversitiesautism spectrum disorderclinical careclinical practicecohortcomparison groupcost effectiveexperiencegenetic disorder diagnosisgenetic informationgenetic variantgenome sequencinggenomic datahigh riskindexinginformation gatheringmemberoutreachpopulation basedpredictive markerprimary outcomeprospectiveresearch clinical testingrisk predictionrisk variantscreeningskillswhole genome
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
The PROGRESS in Autism Center of Excellence will conduct three inter-related Research Projects to
understand how identifying genetic variants associated with high risk for autism shortly after birth predicts risk
for altered neurodevelopmental trajectories and autism diagnosis, and how this identification affects parents’
experience, attitudes, and decision-making. The three proposed PROGRESS Research Projects are built around
a cohort of 240 infants at identified genetic risk (IGR), and 120 infants without identified genetic risk (non-IGR)
found amongst 100,000 healthy newborns screened using genome sequencing from the currently funded
GUARDIAN project. Project 1 will identify genes and genetic variants that increase autism risk using existing
genomic datasets to identify the IGR group prospectively. Project 2 will examine the impact of receiving a
molecular genetic diagnosis on stress, well-being, and decision-making for intervention in parents of the IGR
group. Project 3 will longitudinally assess the IGR group to identify emerging neurodevelopmental (biological,
cognitive, behavioral) markers to predict later autism diagnosis.
The Assessment Core will implement screening at 18 months for children in both groups. Any child
screening positive will either be referred for an expedited evaluation. At 24 months, the Assessment Core will
provide comprehensive, rigorous, standardized, and cost-effective autism diagnostic evaluations of the IGR
group. The result of this evaluation will provide phenotypic and diagnostic information for the PROGRESS
Center’s primary outcome variable – whether or not the child meets the criteria for autism. In addition to providing
screening at 24 months for the non-IGR group (and diagnostic evaluation for those who screen positive), the
Assessment Core will again screen those children in either group who reach 36 months by the end of the project,
and, if positive, refer for an expedited evaluation. The Assessment Core will draw on an experienced team of
pediatric neuropsychologists, psychologists, and psychiatrists who are experts in evaluating autism and other
neurodevelopmental disorders to provide the best estimate diagnosis. The Assessment Core will relay diagnostic
information to parents and coordinate the curation of Assessment Core data with the Statistical and
Computational Analysis (SCA) Core, leveraging the resources of the NYP / Weill Cornell / CU Center for Autism
and the Developing Brain (CADB). Phenotypic information and post-evaluation surveys will be shared with the
Research Projects to accomplish their Aims.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Autism Impact Measure: A New Tool for Treatment Outcome Measurement
-
批准号:8911366
-
项目类别:
-
资助金额:$124.74万
-
财政年份:2013
-
负责人:STEPHEN M KANNE
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: